<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02462876</url>
  </required_header>
  <id_info>
    <org_study_id>FPR14-03</org_study_id>
    <nct_id>NCT02462876</nct_id>
  </id_info>
  <brief_title>Evaluation of the GORE® VIABAHN® Endoprosthesis for the Treatment of Popliteal Artery Aneurysm (PAA)</brief_title>
  <official_title>Post-market Study: Evaluation of the GORE® VIABAHN® Endoprosthesis for the Treatment of Popliteal Artery Aneurysm</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>W.L.Gore &amp; Associates</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>W.L.Gore &amp; Associates</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the long term safety and performance of the GORE® VIABAHN®
      Endoprosthesis for the treatment of patients with Popliteal Artery Aneurysms.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Patency (Performance)</measure>
    <time_frame>12 months</time_frame>
    <description>Primary Patency is defined as blood flow without occlusion maintained through the device after implant without an intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SAEs and AEs (Safety)</measure>
    <time_frame>12 months</time_frame>
    <description>Serious adverse events and adverse events related to the study procedure or the study device</description>
  </primary_outcome>
  <enrollment type="Actual">50</enrollment>
  <condition>Popliteal Artery Aneurysm</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GORE® VIABAHN® Endoprosthesis</intervention_name>
    <description>Treatment of Popliteal Artery Aneurysm with the GORE® VIABAHN® Endoprosthesis.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a symptomatic aneurysm or asymptomatic aneurysm (≥ 2 cm diameter) of the
        popliteal artery, or presence of mural thrombus (&lt; 2 cm) in the popliteal artery treated
        since the date of reimbursement in France.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Inclusion to the study requires the patient:

          1. Received a GORE® VIABAHN® Endoprosthesis to treat a popliteal artery aneurysm

          2. Had a symptomatic aneurysm or asymptomatic aneurysm (≥ 2 cm diameter) of the popliteal
             artery, or the presence of mural thrombus (&lt; 2 cm) in the popliteal artery;

          3. Was 18 years of age or older at the time of the treatment;

          4. Had an elective popliteal artery aneurysm procedure;

          5. Has provided Informed Consent, personally or through lawful representation as
             determined by applicable local regulations and state law

        Exclusion Criteria:

        Prior to or at the time of implant the patient is / has:

          1. Bilateral popliteal artery aneurysms with initial treatment on the same day;

          2. Thrombotic occlusion of the popliteal artery or PAA;

          3. Marfan syndrome or Ehlers-Danlos syndrome;

          4. Unable to tolerate antiplatelet therapy;

          5. Thrombophilia requiring long term anticoagulation;

          6. Known allergies to the GORE® VIABAHN® Endoprosthesis components;

          7. Enrolled in another investigational drug or medical device trial where participation
             may have affected the outcome or treatment of the subject in the popliteal artery
             aneurysm study with the GORE® VIABAHN® Endoprosthesis or had previous surgery for the
             popliteal artery aneurysm in the study limb.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nabil Chakfé</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpitaux Universitaire de Strasbourg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpitaux Universitaire de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2015</study_first_submitted>
  <study_first_submitted_qc>June 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2015</study_first_posted>
  <last_update_submitted>September 26, 2017</last_update_submitted>
  <last_update_submitted_qc>September 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

